Lupin jumped 4.04% to Rs 681.25 after it informed about the launch of Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg.
Lupin's alliance partner Concord Biotech had received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.
Mycophenolic Acid Delayed-Release Tablets USP, 180 mg and 360 mg, is the generic equivalent of Myfortic Delayed-Release Tablets, 180 mg and 360 mg, of Novartis Pharmaceuticals Corporation.
It is indicated for prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant. It is also used in combination with cyclosporine and corticosteroids.
Mycophenolic Acid Delayed-Release Tablets USP had annual sales of approximately $156 million in the U.S. (IQVIA MAT February 2020).
Lupin is an innovation-led transnational pharmaceutical company. The company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
